Accepted for publication December 17, 2022.

The sponsor or funding organization had no role in the design or conduct of this research. Supported in part by an unrestricted grant to the Vanderbilt Eye Institute and Physician Scientist Award from Research to Prevent Blindness, New York, NY. This project was supported by NIH 1R03EB012461, 1R21EY024036, and the National Center for Research Resources, Grant UL1 RR024975-01 (now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was conducted in part using the resources of the Advanced Computing Center for Research and Education at Vanderbilt University, Nashville, TN.

L.M. has been a consultant to Horizon Therapeutics. The other author has no financial or conflicts of interest to disclose.

Correspondence: Louise Mawn, M.D., Vanderbilt Eye Institute, 2311 Pierce Avenue, Nashville, TN 37232 ([email protected])